Age-related Macular Degeneration: An Update on Treatment

American Journal of Medicine

Volumn 121, Issue 4, 2008, Pages 279-281

  Gohel, Parin S ^a   Mandava, Naresh ^a   Olson, Jeffrey L ^a   Durairaj, Vikram D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Anti VEGF; Antiangiogenic therapy; Choroidal neovascularization; Retina; Vision loss

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIOXIDANT; BETA CAROTENE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VERTEPORFIN; ZINC;

AGED; ARTICLE; BLINDNESS; CASE REPORT; CAUCASIAN; CENTRAL SCOTOMA; HUMAN; LASER COAGULATION; LUNG CANCER; MALE; METAMORPHOSIS; PATIENT REFERRAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; UNITED STATES;

EID: 40949134577     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.10.020     Document Type: Note

References (11)

1. Klein R., Klein B.E.K., and Linton K.L.P. Prevalence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 99 (1992) 933-943
2. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 109 (1991) 1109-1114
3. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 104 (1986) 503-512
4. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with vertiporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117 (1999) 1329-1345
5. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119 (2001) 198-207
6. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
7. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
8. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
9. Freeman W.R., and Falkenstein I. Avastin and new treatments for AMD: where are we?. Retina 26 (2006) 853-857
10. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
11. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444